Alzheimer's disease
Pathological changes, recent treatment and future perspectives
Keywords:
Alzheimer, anti-Alzheimer, cholinesterase inhibitors, amyloid bindersAbstract
Alzheimer’s disease (AD) is the most common cause of dementia associated with a progressive neurodegenerative disorder, with a prevalence of 44 million people throughout the world in 2015, and this figure is estimated to double by 2050. This disease is characterized by blood-brain barrier disruption, oxidative stress, mitochondrial impairment, neuroinflammation, and hypometabolism; it is related to amyloid-β peptide accumulation and tau hyperphosphorylation as well as a decrease in acetylcholine levels and a reduction of cerebral blood flow. Studies of potential disease-modifying therapy have generally been undertaken in patients with clinically detectable disease, yet evidence suggests that the pathological changes associated with AD begin several years before this. It is possible that pharmacological therapy may be beneficial in this pre-clinical stage before the neurodegenerative process is established. Techniques providing earlier diagnosis, such as cerebrospinal fluid biomarkers and amyloid positron emission tomography neuroimaging, are key to testing this theory in clinical trials. Recent results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution. Such medicines could potentially delay the onset of dementia and would therefore markedly reduce its prevalence.
Downloads
References
Birks, J. (2006). Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews, 1, CD005593. https://doi.org/10.1002/14651858.CD005593
Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica, 82(4), 239–259. https://doi.org/10.1007/bf00308809
Breijyeh, Z., & Karaman, R. (2020). Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules (Basel, Switzerland), 25(24), 5789. https://doi.org/10.3390/molecules25245789
Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D. R., Price, D. L., & Wong, P. C. (2001). BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nature Neuroscience, 4(3), 233–234. https://doi.org/10.1038/85064
Chung, J., Das, A., Mez, J., Sun, X., Chou, Y.-F., Leung, Y. Y., Thiagalingam, S., Zhang, X., Jun, G. R., Kunkle, B. W., Martin, E. R., Pericak-Vance, M. A., Mayeux, R., Haines, J. L., Schellenberg, G. D., Lunetta, K. L., Pinto, J. M., Wang, L.-S., Ober, C., & Farrer, L. A. (2021). Genome-wide association and multi-omics studies identify MGMT as a novel risk gene for Alzheimer disease among women. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 17 Suppl 3, e054483. https://doi.org/10.1002/alz.054483
Crous-Bou, M., Minguillón, C., Gramunt, N., & Molinuevo, J. L. (2017). Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimer’s Research & Therapy, 9(1). https://doi.org/10.1186/s13195-017-0297-z
Dias, H. K. I., Brown, C. L. R., Polidori, M. C., Lip, G. Y. H., & Griffiths, H. R. (2015). LDL-lipids from patients with hypercholesterolaemia and Alzheimer’s disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention. Clinical Science (London, England: 1979), 129(12), 1195–1206. https://doi.org/10.1042/CS20150351
Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S.-K., Soininen, H., Maetzler, W., Leyhe, T., Bürger, K., Taniguchi, M., Urakami, K., Lista, S., Dubois, B., Blennow, K., & Hampel, H. (2015). CSF biomarkers for the differential diagnosis of Alzheimer’s disease: A large-scale international multicenter study. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 11(11), 1306–1315. https://doi.org/10.1016/j.jalz.2014.12.006
Fattakhov, N., Normatova, S., Madaminov, S., Tilyakhodzhaeva, G., & Abdulkhakimov, A. (2021). Hirudotherapy as an effective method for treatment of migraine - a disease of unknown etiology. International Journal of Health & Medical Sciences, 4(2), 232-237. https://doi.org/10.31295/ijhms.v4n2.1714
Ferreira-Vieira, T. H., Guimaraes, I. M., Silva, F. R., & Ribeiro, F. M. (2016). Alzheimer’s disease: Targeting the cholinergic system. Current Neuropharmacology, 14(1), 101–115. https://doi.org/10.2174/1570159x13666150716165726
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016). Current research therapeutic strategies for Alzheimer’s disease treatment. Neural Plasticity, 2016, 8501693. https://doi.org/10.1155/2016/8501693
Fukui, K., Ferris, H. A., & Kahn, C. R. (2016). Effect of cholesterol reduction on receptor signaling in neurons. The Journal of Biological Chemistry, 291(30), 15910. https://doi.org/10.1074/jbc.a115.664367
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016). Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacological Reports: PR, 68(1), 127–138. https://doi.org/10.1016/j.pharep.2015.07.006
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020). Early diagnosis and targeted treatment strategy for improved therapeutic outcomes in Alzheimer’s disease. Advances in Experimental Medicine and Biology, 1260, 175–191. https://doi.org/10.1007/978-3-030-42667-5_8
Hampel, H., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., Kraft, I., Gasser, T., Leyhe, T., Möller, H.-J., Kurz, A., & Basun, H. (2009). Lithium trial in Alzheimer’s disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. The Journal of Clinical Psychiatry, 70(6), 922–931. https://doi.org/10.4088/jcp.08m04606
Hampel, H., Vergallo, A., Afshar, M., Akman-Anderson, L., Arenas, J., Benda, N., Batrla, R., Broich, K., Caraci, F., Cuello, A. C., Emanuele, E., Haberkamp, M., Kiddle, S. J., Lucía, A., Mapstone, M., Verdooner, S. R., Woodcock, J., & Lista, S. (2019). Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease. Dialogues in Clinical Neuroscience, 21(2), 177–191. https://doi.org/10.31887/dcns.2019.21.2/hhampel
Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., & Hansson, O. (2010). Evaluation of CSF biomarkers as predictors of Alzheimer’s disease: a clinical follow-up study of 4.7 years. Journal of Alzheimer’s Disease: JAD, 21(4), 1119–1128. https://doi.org/10.3233/jad-2010-100207
Jatoi, S., Hafeez, A., Riaz, S. U., Ali, A., Ghauri, M. I., & Zehra, M. (2020). Low vitamin B12 levels: An underestimated cause of minimal cognitive impairment and dementia. Cureus, 12(2), e6976. https://doi.org/10.7759/cureus.6976
Kim, S., Swaminathan, S., Shen, L., Risacher, S. L., Nho, K., Foroud, T., Shaw, L. M., Trojanowski, J. Q., Potkin, S. G., Huentelman, M. J., Craig, D. W., DeChairo, B. M., Aisen, P. S., Petersen, R. C., Weiner, M. W., Saykin, A. J., & Alzheimer’s Disease Neuroimaging Initiative. (2011). Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology, 76(1), 69–79. https://doi.org/10.1212/WNL.0b013e318204a397
Kumar, A., Sidhu, J., Goyal, A., & Tsao, J. W. (2021). Alzheimer Disease. In StatPearls [Internet]. StatPearls Publishing.
Larner, A. J. (2010). Cholinesterase inhibitors: beyond Alzheimer’s disease. Expert Review of Neurotherapeutics, 10(11), 1699–1705. https://doi.org/10.1586/ern.10.105
Lemere, C. A. (2013). Immunotherapy for Alzheimer’s disease: hoops and hurdles. Molecular Neurodegeneration, 8(1), 36. https://doi.org/10.1186/1750-1326-8-36
Leung, K.-C., Li, V., Ng, Y.-Z., Chan, T.-T., Chang, R. S., & Wong, R. Y. (2017). Systematic review of cholinesterase inhibitors on cognition and behavioral symptoms in patients of Chinese descent with Alzheimer’s disease, vascular dementia, or mixed dementia. Geriatrics (Basel, Switzerland), 2(3), 29. https://doi.org/10.3390/geriatrics2030029
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Jr, Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 7(3), 263–269. https://doi.org/10.1016/j.jalz.2011.03.005
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34(7), 939–944. https://doi.org/10.1212/wnl.34.7.939
Mosconi, L., Berti, V., Glodzik, L., Pupi, A., De Santi, S., & de Leon, M. J. (2010). Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging. Journal of Alzheimer’s Disease: JAD, 20(3), 843–854. https://doi.org/10.3233/JAD-2010-091504
P. Bhatt, S. Singh, S. Kumar Sharma, and S. Rabiu, “Development and characterization of fast dissolving buccal strip of frovatriptan succinate monoydrate for buccal delivery,” Int. J. Pharm. Investig., vol. 11, no. 1, pp. 69–75, 2021.
Pankaj, “Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy,” J. Pharm. Res. Int., pp. 54–63, 2021.
Pankaj, “Cyclodextrin modified block polymer for oral chemotherapy,” J. Pharm. Res. Int., pp. 21–29, 2021.
Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Paris, F., Santamato, A., D’Onofrio, G., Logroscino, G., Pilotto, A., & Solfrizzi, V. (2011). Anti-β-amyloid immunotherapy for Alzheimer’s disease: focus on bapineuzumab. Current Alzheimer Research, 8(8), 808–817. https://doi.org/10.2174/156720511798192718
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., Rodriguez Martinez de Liano, S., Liu, E., Koller, M., Gregg, K. M., Schenk, D., Black, R., & Grundman, M. (2010). 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology, 9(4), 363–372. https://doi.org/10.1016/S1474-4422(10)70043-0
Sharma, K. (2019). Cholinesterase inhibitors as Alzheimer’s therapeutics (Review). Molecular Medicine Reports, 20(2), 1479–1487. https://doi.org/10.3892/mmr.2019.10374
Silverman, W., Wisniewski, H. M., Bobinski, M., & Wegiel, J. (1997). Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiology of Aging, 18(4), 377–379; discussion 389-92. https://doi.org/10.1016/s0197-4580(97)00051-1
Singh, R., & Sadiq, N. M. (2022). Cholinesterase Inhibitors. In StatPearls [Internet]. StatPearls Publishing.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. International Journal of Health Sciences, 5(2), vi-ix. https://doi.org/10.53730/ijhs.v5n2.2937
Tayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013). Bapineuzumab and solanezumab for Alzheimer’s disease: is the “amyloid cascade hypothesis” still alive? Expert Opinion on Biological Therapy, 13(7), 1075–1084. https://doi.org/10.1517/14712598.2013.789856
Vandenberghe, R., Adamczuk, K., & Van Laere, K. (2013). The interest of amyloid PET imaging in the diagnosis of Alzheimer’s disease. Current Opinion in Neurology, 26(6), 646–655. https://doi.org/10.1097/WCO.0000000000000036
Wang, R., & Reddy, P. H. (2017). Role of glutamate and NMDA receptors in Alzheimer’s disease. Journal of Alzheimer’s Disease: JAD, 57(4), 1041–1048. https://doi.org/10.3233/JAD-160763
Whitehouse, P. J., Price, D. L., Struble, R. G., Clark, A. W., Coyle, J. T., & Delon, M. R. (1982). Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science (New York, N.Y.), 215(4537), 1237–1239. https://doi.org/10.1126/science.7058341
Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2014). Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochemical Pharmacology, 88(4), 529–539. https://doi.org/10.1016/j.bcp.2013.12.008
Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015). Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease. Journal of Alzheimer’s Disease: JAD, 44(2), 705–720. https://doi.org/10.3233/JAD-142874
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
